glp-1 analog drugs analogs, new trend in obesity treatment, become even more effective < Pharma < Article Frontiers | GLP−1 receptor agonists

Lilly is also advancing oral GLP-1 agonists

It appears to act as an exercise-responsive endocrine signal that enhances metabolic flexibility without directly suppressing appetite or altering central satiety circuits

These are not published trials

GLP-1 Drugs and Eating Disorders: A Hidden Risk in the Weight Loss Revolution By Donnisa Edmonds, C2ST Intern, University of Chicago In 2021, the FDA announced that they had approved Wegovy, a GLP-1 receptor agonist, as a treatment for chronic weight management

Effects of Semaglutide Treatment on Psoriatic Lesions in Obese Patients with Type 2 Diabetes Mellitus: An Open-Label, Randomized Clinical Trial

MARKET ECOSYSTEM The GLP-1 agonists ecosystem encompasses a network of interdependent stakeholders, including drug manufacturers, contract research and manufacturing organizations, healthcare providers, and end users